Insmed (INSM) Misses Q4 EPS by 30c

Insmed (NASDAQ: INSM) reported Q4 EPS of ($1.00), $0.30 worse than the analyst estimate of ($0.70). Revenue for the quarter came in at $41.42 million versus the consensus estimate of $41.44 million.

"2020 was the most productive and significant year in Insmed's history, as we evolved from a single-product company with a successful U.S. launch to a truly global organization advancing three distinct, value-creating programs. I am incredibly proud of our team's performance, which is all the more exemplary against the backdrop of COVID-19," commented Will Lewis, Chair and Chief Executive Officer of Insmed. "In the fourth quarter, we initiated both the Phase 3 ASPEN study of brensocatib in patients with bronchiectasis and the ARIKAYCE frontline clinical trial program in patients with NTM lung disease caused by MAC; advanced our ARIKAYCE launch in Europe and prepared for a potential approval and launch in Japan while maintaining steady performance in the U.S.; and advanced the development of TPIP, for which we announced positive Phase 1 data just last week. We begin 2021 with incredible momentum and believe we have the capabilities and talent to achieve our ambitious vision."

For earnings history and earnings-related data on Insmed (INSM) click here.

You May Also Be Interested In

• Corpay agrees to $100M FTC settlement over marketing practices
• UBS Reiterates Neutral Rating on Intuit (INTU), Says Investor Day Not 'Sentiment-Changing'
• Circle Internet stock climbs on TD Cowen upgrade, Fed rate hike